Perspective: COVID-19, implications of nasal diseases and consequences for their management - 22/07/20


Key words : SARS-CoV-2, COVID-19, chronic rhinosinusitis, allergy, corticosteroids, biologics
El texto completo de este artículo está disponible en PDF.
Disclosure of potential conflict of interest: C. Bachert acted as speaker and member of advisory boards for Sanofi-Aventis, Novartis, Glaxo, Astra-Zeneca, Stallergenes, ALK, and Mylan. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 146 - N° 1
P. 67-69 - juillet 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.